Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
- Revenue in JPY (TTM)4.17tn
- Net income in JPY178.22bn
- Incorporated1925
- Employees49.10k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin Co Ltd | 442.23bn | 81.19bn | 1.44tn | 5.97k | 17.68 | 1.72 | 14.09 | 3.26 | 151.01 | 151.01 | 822.55 | 1,555.81 | 0.4499 | 1.57 | 3.81 | 74,026,450.00 | 8.26 | 6.28 | 9.43 | 7.08 | 74.85 | 75.45 | 18.36 | 14.96 | 4.05 | -- | 0.023 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
| Eisai Co Ltd | 749.46bn | 45.42bn | 1.78tn | 11.08k | 37.96 | 2.11 | 20.67 | 2.38 | 158.37 | 158.37 | 2,613.15 | 2,852.93 | 0.585 | 1.11 | 4.00 | 67,665,220.00 | 3.65 | 5.94 | 4.86 | 8.12 | 78.95 | 75.43 | 6.23 | 9.58 | 1.79 | -- | 0.1648 | 68.53 | -1.56 | 4.41 | 15.59 | 1.35 | 6.92 | 1.30 |
| Shionogi & Co Ltd | 425.16bn | 154.46bn | 2.22tn | 5.68k | 13.71 | 1.74 | 13.02 | 5.23 | 527.99 | 527.99 | 1,453.13 | 4,149.67 | 0.3244 | 0.9783 | 2.67 | 74,851,410.00 | 11.69 | 13.45 | 13.23 | 15.20 | 85.87 | 83.95 | 36.02 | 38.01 | 6.01 | -- | 0.008 | 25.23 | 27.32 | 4.36 | 61.99 | 11.18 | 16.93 | 10.49 |
| Astellas Pharma Inc | 1.54tn | 4.20bn | 2.62tn | 14.48k | 585.64 | 1.72 | 19.18 | 1.70 | 2.47 | 2.47 | 856.92 | 838.41 | 0.5247 | 1.45 | 3.26 | 106,553,700.00 | 0.1427 | 6.93 | 0.2087 | 9.72 | 81.76 | 79.67 | 0.272 | 11.41 | 0.7143 | 130.30 | 0.3669 | 56.13 | 17.16 | 3.15 | -20.45 | -9.73 | 17.06 | 10.76 |
| Otsuka Holdings Co Ltd | 2.02tn | 121.61bn | 3.54tn | 34.39k | 28.32 | 1.44 | 15.85 | 1.75 | 224.09 | 224.09 | 3,719.71 | 4,410.81 | 0.6246 | 2.58 | 4.50 | 58,699,780.00 | 3.88 | 4.80 | 4.85 | 5.88 | 69.72 | 68.21 | 6.22 | 8.36 | 1.61 | -- | 0.0808 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Takeda Pharmaceutical Co Ltd | 4.17tn | 178.22bn | 6.48tn | 49.10k | 36.31 | 0.9529 | 7.36 | 1.55 | 112.79 | 112.79 | 2,647.34 | 4,297.22 | 0.3007 | 1.29 | 5.86 | 84,917,990.00 | 1.29 | 1.79 | 1.54 | 2.14 | 67.52 | 68.57 | 4.28 | 6.81 | 0.5518 | 2.83 | 0.4089 | 121.86 | 12.85 | 17.87 | 37.80 | 11.15 | 37.64 | 0.00 |
| Chugai Pharmaceutical Co Ltd | 1.11tn | 325.47bn | 8.57tn | 7.60k | 25.81 | 5.17 | -- | 7.71 | 197.80 | 197.80 | 675.40 | 988.01 | 0.5846 | 1.46 | 2.67 | 146,155,400.00 | 17.12 | 19.29 | 21.06 | 23.91 | 62.81 | 63.55 | 29.29 | 28.39 | 3.79 | -- | 0.0082 | 40.14 | -11.78 | 13.90 | -13.08 | 28.61 | -0.8947 | 27.23 |
| Daiichi Sankyo Co Ltd | 1.50tn | 186.05bn | 8.88tn | 17.44k | 47.04 | 5.51 | 35.26 | 5.91 | 96.97 | 96.97 | 783.61 | 827.32 | 0.5306 | 1.27 | 3.69 | 86,232,860.00 | 6.59 | 4.43 | 8.11 | 5.40 | 72.28 | 66.08 | 12.41 | 9.13 | 2.84 | -- | 0.0603 | 53.12 | 22.36 | 5.89 | 62.63 | 13.68 | 12.13 | 5.15 |
Data as of Apr 16 2024. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
22.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 69.37m | 4.38% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 54.43m | 3.44% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 13 Oct 2023 | 50.89m | 3.22% |
| Nikko Asset Management Co., Ltd.as of 13 Oct 2023 | 34.71m | 2.19% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 34.27m | 2.17% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 31.49m | 1.99% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 25.88m | 1.64% |
| Capital International Ltd.as of 31 Dec 2023 | 22.56m | 1.43% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 17.59m | 1.11% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 16.76m | 1.06% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
